OPN-9652 / Opna Bio - LARVOL DELTA

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models. (PubMed, Nat Commun) - "In vivo, OPN-9652 delays the onset of acquired resistance to BRAF inhibitors and MEK inhibitors from minimal residual disease. Thus, TAZ-TEAD activity plays an important role in melanoma drug tolerance and the development of acquired resistance."

Journal • Minimal residual disease • Melanoma • Oncology • Solid Tumor • CCN1 • CTGF • SOX10

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting (Businesswire) - "Opna Bio...presented promising preclinical data in...programs...OPN-9840, an oral, non-covalent TEAD inhibitor in malignant mesothelioma and metastatic melanoma. Data were shared at the American Association of Cancer Research (AACR) Annual Meeting....Significantly inhibited tumor growth (88% to >100%) in an NF2-mutant malignant mesothelioma mouse xenograft model. Tumor regression was observed in the 15 mg/kg (2/8 mice) and 50 mg/kg (4/8 mice) dose groups. OPN-9652, an analog of OPN-9840, showed increased anti-tumor activity (134% TGI) and synergistic inhibition of downstream target genes in a combination study with trametinib."

Preclinical • Melanoma • Mesothelioma

OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models (AACR 2024) - "In summary, OPN-9840 is a potent pan-TEAD inhibitor that shows monotherapy efficacy in MM. As we observed synergy between another pan-TEAD inhibitor, OPN-9652, with trametinib, we are exploring synergy of OPN-9840 with additional targeted therapies in tumor types beyond MM."

Preclinical • Mesothelioma • Oncology • Solid Tumor • ANKRD1 • CCN1 • CTGF • NF2 • TEAD1 • TP53